Formulation Development
Purple Biotech Granted New Patent for NT219 in Combination With EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Purple Biotech Ltd. recently announced the U.S. Patent and Trademark Office has issued a patent for NT219 used in combination with epidermal growth factor receptor…
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
atai Life Sciences recently announced the completion of patient enrollment in the eight-week, double-blind, core stage of the global Phase 2b clinical trial evaluating BPL-003 (mebufotenin…
Lisata Therapeutics & GATC Health Consummate First Step in Strategic Collaboration to Use AI to Derisk & Accelerate Drug Development
Lisata Therapeutics, Inc. and GATC Health Corp recently announced the consummation of the first step of an intended multi-part strategic agreement. Under terms of the…
Axplora Expands Commercial Payload Production Capabilities at Le Mans to Strengthen its Leading Position in ADC Manufacturing
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial manufacturing of ADCs with…
Jupiter Neurosciences & Aquanova AG Announce Strategic Collaboration to Develop Longevity & Healthspan Products
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, today announced a strategic partnership with…
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured…
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospita
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment…
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral…
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces top-line…
Abzena Strengthens Executive Leadership Team With The Appointment of Taylor Boyd as CBO
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor Boyd has joined the company as its…
Veranova Relocates Headquarters to Devens, MA
Veranova is pleased to announce the move of its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for manufacturing and…
Traws Pharma Reports Positive Results From an Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory…
Lexicon Pharmaceuticals Announces Topline Results From Phase 2b Study Evaluating Pilavapadin in Adults With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. recently announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor…
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
Revive Therapeutics Ltd. recently announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full…
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central…
WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug…
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Neurona Therapeutics recently announced plans to initiate the Phase 3 EPIC clinical trial for its lead product candidate, NRTX-1001. NRTX-1001 is the first investigational human cell…
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
Phoenix Molecular Designs recently announced the dosing of the first patient in their Phase 2 clinical trial, Dauntless-1. The Dauntless-1 trial will evaluate the therapeutic potential…
Tiziana Life Sciences Announces Agreement for Product Development Services With Renaissance Lakewood
Tiziana Life Sciences, Ltd. recently announced a product development services agreement with Renaissance Lakewood LLC, a leading Contract Development and Manufacturing Organization (CDMO) focused on…
Medigene AG Expands Patent Portfolio With Patent Grant for its JOVI Technology in the US
Medigene AG recently announced it has been issued a patent by the US Patent Office protecting its JOVI technology, a method allowing the enrichment of…
